Pharmacogenomics: Genes Impacting Drug Response

Pharmacogenomics in the Real World: A Look at Top Genes Impacting Drug Response

Pharmacogenomics is no longer a distant promise of personalized medicine. It’s already reshaping how we approach treatment decisions in research and clinical settings. With next-generation sequencing (NGS) panels, scientists can now screen for multiple pharmacogenes at once, building more insightful profiles to guide drug response. Paragon Genomics supports this shift through CleanPlex Custom NGS Panels, which make it easier to develop targeted, high-performance assays for pharmacogenomics applications.

What Is the Role of Pharmacogenomics in Drug Development?

Pharmacogenomics plays a growing role in the drug development process. By identifying how genetic differences affect drug response, researchers can design more targeted therapies and select better candidates for clinical trials. This approach helps reduce the risk of adverse reactions, improve drug efficacy, and speed up the path to approval.

Top Genes That Influence Drug Response

Some genes play an important role in how the body processes medications, which affects everything from how well a drug works to potential side effects. These pharmacogenes impact drug metabolism, transport, and response, and are often the focus of targeted pharmacogenomics testing. Below are several of the most well-studied genes in this space:

• CYP2D6: Involved in metabolizing over 20% of commonly prescribed drugs, including antidepressants, opioids, and beta-blockers. Variants can lead to poor, intermediate, or ultra-rapid metabolism.
• CYP2C19: Plays a role in processing drugs like clopidogrel, proton pump inhibitors, and certain antidepressants. Genetic differences can affect whether a patient responds well or not at all.
• VKORC1: Affects sensitivity to warfarin, a widely used blood thinner. Variants in this gene influence how much medication a patient needs to achieve safe, effective blood thinning.
• TPMT: Impacts metabolism of thiopurine drugs used in cancer and autoimmune conditions. Low TPMT activity increases the risk of toxicity if standard doses are given.
• SLCO1B1: Influences how statins are transported in the body. Certain variants raise the risk of muscle-related side effects, especially with higher statin doses.

By identifying variations in these and other pharmacogenes, researchers and clinicians can better predict drug response and adjust treatment accordingly. Using a customizable NGS panel makes it easy to focus on the genes most relevant to your research or clinical goals.

What are the Benefits of Pharmacogenomics?

Pharmacogenomics offers several real-world advantages:

• Personalized medicine: Treatment plans can be customized to align with a person’s unique genetic profile.
• Improved drug efficacy: Optimized drug and dosage decisions lead to more effective outcomes.
• Reduced adverse reactions: Genetic variants that increase risk can be flagged in advance.
• Lower healthcare costs: Avoiding ineffective medications and reducing side effects helps cut unnecessary spending.

Pharmacogenomics and Randomized Controlled Trials

Pharmacogenomics is increasingly being integrated into randomized controlled trials (RCTs). Genetic information helps researchers design smarter studies by selecting participants based on drug metabolism profiles or known variants. This improves the ability to detect true treatment effects and reduces variability caused by individual differences in drug response.

By including pharmacogenomic data, RCTs can better evaluate how personalized treatment strategies perform compared to standard approaches, laying the groundwork for future clinical adoption.

Does Genetic Profiling Matter for Precision Medicine?

Yes. Understanding how a person’s genes affect their response to medications can change how healthcare providers approach drug therapy. Instead of using a trial-and-error method, genetic profiling offers a path toward more personalized, predictable outcomes.

By identifying genetic variants in drug-metabolizing enzymes, providers can adjust medication type or dose before prescribing. This can lead to fewer adverse drug reactions, better drug efficacy, and more targeted care.

As mentioned, NGS panels support this approach by making it easier to screen for a wide range of pharmacogenes in a single, efficient test. With customizable panels from Paragon Genomics, researchers and clinicians can focus on the specific variants and genes that matter most in their area of drug therapy.

How NGS Panels Support Pharmacogenomics Research

Amplicon-based next-generation sequencing has become one of the most effective ways to profile pharmacogenes. It allows researchers and assay developers to target specific genes involved in drug metabolism, efficacy, and toxicity, helping identify variants that impact how individuals respond to commonly prescribed drugs.

CleanPlex® Custom NGS Panels from Paragon Genomics provide a fast, scalable, and cost-effective solution for pharmacogenomics research. Whether you’re working with blood, saliva, buccal swabs, or extracted DNA, the panels are designed to deliver high-quality results from a wide range of sample types. Some of the key benefits include:

• Scalable high-throughput performance: Analyze thousands of pharmacogenomic markers in one streamlined assay.
• Fast turnaround: Receive custom-designed assays within 4 to 6 weeks, with expert support from start to finish.
• Cost-efficient processing: Compatible with the Illumina® platform, the system minimizes consumable use and reduces waste.
• Automation-friendly workflow: Prepare sequencing-ready libraries in just three hours with a simple protocol that supports automation.
• Reliable, reproducible data: Achieve high marker call rates and strong sequencing efficiency for confident decision-making.

CleanPlex panels are built for flexibility, allowing you to customize your assay based on the population you’re studying and the drugs most relevant to your clinical or research goals. With a focus on precision and simplicity, these tools help move pharmacogenomics from theory into routine practice.

What Are the Limitations of Pharmacogenomics?

Currently, there are several limitations, including:

• Genetic Factors: While pharmacogenomics holds promise, not all drug responses can be explained by genetics alone. Drug metabolism is influenced by both genetic and environmental factors (age, diet, liver function, and interactions with other commonly prescribed drugs). Many drug responses involve complex inheritance patterns with multiple genes playing a role, which can make prediction difficult.
• Adverse Drug Reactions: Even with genetic testing, some adverse drug reactions still occur due to factors outside the tested gene set. For example, rare genetic variants not included in standard panels might go undetected. This is why ongoing research and updates to gene panels are necessary to reduce the chance of missing relevant risks.
• Drug Metabolism: Genetic differences in drug metabolizing enzymes such as CYP2D6 and CYP2C19 affect how fast or slow a person processes certain medications. However, not all variants have well-established links to clinical outcomes. For some drugs, the connection between genotype and metabolism remains unclear.
• Clinical Practice: In routine clinical practice, pharmacogenomic testing is still not widely adopted. The reasons include cost, lack of insurance coverage, and limited awareness among healthcare providers. There is also a lack of standardization in how testing is performed and how results are interpreted. This can lead to inconsistent recommendations and limit clinical utility.
• Ethnic Variability: Genetic variation differs across populations. A test built for one group might not provide accurate predictions for another. To be effective in diverse settings, pharmacogenomics panels must reflect the full range of genetic diversity, another reason customization matters.
• Ethical and Legal Issues: Pharmacogenomic testing raises valid concerns around privacy, informed consent, and the potential misuse of genetic information. As testing becomes more common in healthcare, clear guidelines are needed to protect patients from discrimination and data misuse.